This somewhat general article discusses various radiation options for prostate cancer, including: High Dose Rate brachytherapy – a form of focal therapy High fraction external beam radiotherapy Read the article.
Advances in Radiation Treatment for Prostate Cancer Read More »
November 2014 Scotiabank Awareness Night Radiation Therapy: Where we 2014 and where we are going Dr. Padraig Warde, MB, ChB, BAO, FRCPC Princess Margaret Cancer Centre Professor, Dept of Radiation Oncology, U of Toronto Staff Radiation Oncologist, Princess Margaret Hospital/University Health Network Provincial Head, Radiation Treatment Program Cancer Care Ontario CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 47:12 minutes
Video: Dr. Padraig Warde, “Radiation Therapy: Where we are 2014 and where we are going” Read More »
July 2015 Scotiabank Awareness Night Radiation and Hormone Therapy Dr. Gerard Morton, MB BCh BAO, MRCPI, FRCPC, FFRRCSI Associate Professor , Department of Radiation Oncology, University of Toronto Radiation Oncologist, Sunnybrook Odette Cancer Centre Head of Brachytherapy, Sunnybrook Odette Cancer Centre Chair, Ontario Association of Radiation Oncologists Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 43:11 minutes
Video: Dr. Gerard Morton, “Radiation and Hormone Therapy” Read More »
Active surveillance — in which prostate cancer is regularly monitored for signs of progression — spares men whose tumors may never progress from potential treatment-associated adverse effects, such as sexual dysfunction or incontinence. Proponents contend active surveillance is a viable option because mortality rates among men whose tumors are limited to the prostate are low, and many of these men never experience symptoms from their disease. However, some urologic oncologists question active surveillance as a standard management strategy and contend its use should be limited. Read the article.
Active surveillance redefines paradigm for prostate cancer management Read More »
Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally advanced prostate cancer treated with radiotherapy. Read the article.
Long-term ADT Best for Locally Advanced Prostate Cancer Read More »
The addition of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial. Read the article.
Combining Radiotherapy With Anti-Androgen Improves Prostate Cancer Survival Read More »
Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn’t have heart problems lived longer if they had both treatments, the researchers added. Read the article.
Some Prostate Cancer Patients May Not Benefit From Hormone Therapy Read More »
High-dose-rate (HDR) brachytherapy was originally used with external beam radiation therapy (EBRT) to increase the dose to the prostate without injuring the bladder or rectum. Numerous studies have reported HDR brachytherapy is safe and effective. It has been adapted for use without EBRT for cases not requiring lymph node treatment. Read the article.
High-dose-rate brachytherapy (HDRBT) monotherapy — 10 year results Read More »
Delaying surgery does not appear to harm men on active surveillance (AS) for prostate cancer (PCa), a new study finds. Over 3 years after radical surgery, men who delayed surgery and those who had immediate surgery had similar rates of biochemical recurrence. Read the article.
Delaying RP with Active Surveillance Carries No Greater Risks Read More »
PSA production may be lower in African-American than Caucasian men with low-risk prostate cancer (PCa), a new study suggests. If confirmed, the finding could impact active surveillance criteria for black patients. Read the article.
Black Men with Low-Risk Prostate Cancer Produce Less PSA Read More »